[
  {
    "ts": null,
    "headline": "Correction to Eli Lilly Receives Approval for Crohn's Treatment Article",
    "summary": "Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. Eli Lilly Receives FDA Approval for Crohn's Disease Treatment, at 4:25 p.m. ET, and in a subsequent update, incorrectly...",
    "url": "https://finnhub.io/api/news?id=db3f404ee19151468db504ed8d6b6534dc9fc68388efa514a50e4c5cbb6bafa0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736964908,
      "headline": "Correction to Eli Lilly Receives Approval for Crohn's Treatment Article",
      "id": 132402146,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. Eli Lilly Receives FDA Approval for Crohn's Disease Treatment, at 4:25 p.m. ET, and in a subsequent update, incorrectly...",
      "url": "https://finnhub.io/api/news?id=db3f404ee19151468db504ed8d6b6534dc9fc68388efa514a50e4c5cbb6bafa0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment",
    "summary": "By Connor Hart Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes...",
    "url": "https://finnhub.io/api/news?id=b5f9b41886b90dd97499137684ecd742358e71b134f7efc52517ebc4c2b41a11",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736959273,
      "headline": "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment",
      "id": 132401640,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Connor Hart Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes...",
      "url": "https://finnhub.io/api/news?id=b5f9b41886b90dd97499137684ecd742358e71b134f7efc52517ebc4c2b41a11"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment",
    "summary": "Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment",
    "url": "https://finnhub.io/api/news?id=a89a9cffdd76b3240a336e0939f3000a5430407e0ceca0e06124b3633eedf950",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736958660,
      "headline": "Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment",
      "id": 132407683,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly Receives FDA Approval for Crohn’s Disease Treatment",
      "url": "https://finnhub.io/api/news?id=a89a9cffdd76b3240a336e0939f3000a5430407e0ceca0e06124b3633eedf950"
    }
  },
  {
    "ts": null,
    "headline": "After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.",
    "summary": "After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.",
    "url": "https://finnhub.io/api/news?id=efc91610006206ab31570735b136449d36c93bb7c5af65fa8c759c6a8560ca9f",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736958202,
      "headline": "After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.",
      "id": 132407684,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.",
      "url": "https://finnhub.io/api/news?id=efc91610006206ab31570735b136449d36c93bb7c5af65fa8c759c6a8560ca9f"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease",
    "summary": "In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one yearAmong those who achieved clinical...",
    "url": "https://finnhub.io/api/news?id=5ccebabf9be0372ab0eb78bfea04ff7b2fa993d9e6f6219120ed7f8232175348",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736957285,
      "headline": "FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease",
      "id": 132401443,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one yearAmong those who achieved clinical...",
      "url": "https://finnhub.io/api/news?id=5ccebabf9be0372ab0eb78bfea04ff7b2fa993d9e6f6219120ed7f8232175348"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Big 2025 Ahead, But Execution Risks Exist",
    "summary": "Analysis of Eli Lilly and Company's stock performance and prospects in the dynamic weight-loss drug market, offering investment insights. Click for this LLY update.",
    "url": "https://finnhub.io/api/news?id=7be9aea112fba7be5b7ff042adf15d675eb30e06a564f6a27bc209b78056cf78",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736954282,
      "headline": "Eli Lilly: Big 2025 Ahead, But Execution Risks Exist",
      "id": 132401266,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162809200/image_2162809200.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Analysis of Eli Lilly and Company's stock performance and prospects in the dynamic weight-loss drug market, offering investment insights. Click for this LLY update.",
      "url": "https://finnhub.io/api/news?id=7be9aea112fba7be5b7ff042adf15d675eb30e06a564f6a27bc209b78056cf78"
    }
  },
  {
    "ts": null,
    "headline": "As Lilly Stock Tumbles on GLP-1 Demand Worries, CEO Says All Is Well",
    "summary": "As Lilly Stock Tumbles on GLP-1 Demand Worries, CEO Says All Is Well",
    "url": "https://finnhub.io/api/news?id=393635d573935ba9bb0579959563c39666b126459b59a1adb009fdfc7d67c2ec",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736934420,
      "headline": "As Lilly Stock Tumbles on GLP-1 Demand Worries, CEO Says All Is Well",
      "id": 132407702,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "As Lilly Stock Tumbles on GLP-1 Demand Worries, CEO Says All Is Well",
      "url": "https://finnhub.io/api/news?id=393635d573935ba9bb0579959563c39666b126459b59a1adb009fdfc7d67c2ec"
    }
  },
  {
    "ts": null,
    "headline": "Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly",
    "summary": "Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly",
    "url": "https://finnhub.io/api/news?id=274fad9e32c783cfb852bd411bd208cc04742751598f620bcd57de0d6800ba84",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736930185,
      "headline": "Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly",
      "id": 132407685,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Option Trade Could Return More Than $1,300 On A Wobbly Eli Lilly",
      "url": "https://finnhub.io/api/news?id=274fad9e32c783cfb852bd411bd208cc04742751598f620bcd57de0d6800ba84"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.",
    "summary": "Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=2e7855d8fc1840fa8fcb54920f1d98e6e8045b778840ef06702338f953e57190",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736924100,
      "headline": "Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.",
      "id": 132407300,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=2e7855d8fc1840fa8fcb54920f1d98e6e8045b778840ef06702338f953e57190"
    }
  }
]